PURPOSE: The purpose of this study was to analyze results of adjuvant stereotactic radiosurgery (SRS) targeted at resection cavities of brain metastases without whole-brain irradiation (WBI). METHODS AND MATERIALS: Patients who underwent SRS to the tumor bed, deferring WBI after resection of a brain metastasis, were retrospectively identified. RESULTS: Seventy-two patients with 76 cavities treated from 1998 to 2006 met inclusion criteria. The SRS was delivered to a median marginal dose of 18.6 Gy (range, 15-30 Gy) targeting an average tumor volume of 9.8 cm(3) (range, 0.1-66.8 cm(3)). With a median follow-up of 8.1 months (range, 0.1-80.5 months), 65 patients had follow-up imaging assessable for control analyses. Actuarial local control rates at 6 and 12 months were 88% and 79%, respectively. On univariate analysis, increasing values of conformality indices were the only treatment variables that correlated significantly with improved local control; local control was 100% for the least conformal quartile compared with 63% for the remaining quartiles. Target volume, dose, and number of sessions were not statistically significant. CONCLUSIONS: In this retrospective series, SRS administered to the resection cavity of brain metastases resulted in a 79% local control rate at 12 months. This value compares favorably with historic results with observation alone (54%) and postoperative WBI (80-90%). Given the improved local control seen with less conformal plans, we recommend inclusion of a 2-mm margin around the resection cavity when using this technique.
PURPOSE: The purpose of this study was to analyze results of adjuvant stereotactic radiosurgery (SRS) targeted at resection cavities of brain metastases without whole-brain irradiation (WBI). METHODS AND MATERIALS: Patients who underwent SRS to the tumor bed, deferring WBI after resection of a brain metastasis, were retrospectively identified. RESULTS: Seventy-two patients with 76 cavities treated from 1998 to 2006 met inclusion criteria. The SRS was delivered to a median marginal dose of 18.6 Gy (range, 15-30 Gy) targeting an average tumor volume of 9.8 cm(3) (range, 0.1-66.8 cm(3)). With a median follow-up of 8.1 months (range, 0.1-80.5 months), 65 patients had follow-up imaging assessable for control analyses. Actuarial local control rates at 6 and 12 months were 88% and 79%, respectively. On univariate analysis, increasing values of conformality indices were the only treatment variables that correlated significantly with improved local control; local control was 100% for the least conformal quartile compared with 63% for the remaining quartiles. Target volume, dose, and number of sessions were not statistically significant. CONCLUSIONS: In this retrospective series, SRS administered to the resection cavity of brain metastases resulted in a 79% local control rate at 12 months. This value compares favorably with historic results with observation alone (54%) and postoperative WBI (80-90%). Given the improved local control seen with less conformal plans, we recommend inclusion of a 2-mm margin around the resection cavity when using this technique.
Authors: Anthony L Asher; Mohammed Ali Alvi; Mohamad Bydon; Nader Pouratian; Ronald E Warnick; James McInerney; Inga S Grills; Jason Sheehan Journal: J Neurooncol Date: 2021-01-22 Impact factor: 4.130
Authors: Anthony Pham; Menachem Z Yondorf; Bhupesh Parashar; Ronald J Scheff; Susan C Pannullo; Rohan Ramakrishna; Philip E Stieg; Theodore H Schwartz; A Gabriella Wernicke Journal: J Neurooncol Date: 2015-12-09 Impact factor: 4.130
Authors: Che-Chuan Wang; Scott R Floyd; Chin-Hong Chang; Peter C Warnke; Chung-Ching Chio; Ekkehard M Kasper; Anand Mahadevan; Eric T Wong; Clark C Chen Journal: J Neurooncol Date: 2011-08-31 Impact factor: 4.130
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Steven W Hwang; Mohab M Abozed; Andrew Hale; Rebecca L Eisenberg; Tomas Dvorak; Kevin Yao; Rolf Pfannl; John Mignano; Jay-Jiguang Zhu; Lori Lyn Price; Gary M Strauss; Julian K Wu Journal: J Neurooncol Date: 2009-11-12 Impact factor: 4.130